EAY191-N4 ComboMATCH (Ovarian and Endometrial Cancers) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.
What is the Condition Being Studied?
Ovarian or Endometrial Cancer
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with ovarian, primary peritoneal, fallopian tube, or endometrial cancer
- Have documented RAS pathway mutations
- Are able to have a safe biopsy of their tumor(s) performed or have a biopsy that was done in the last 12 months that confirms tumor mutations
- Have disease that has returned after treatment or is not responding to treatment
For more information about this study, please contact the study team at nick.jeffries@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will be randomly assigned (like a coin flip) to 1 of 2 groups:
- Group 1 will get a regimen of selumetinib and olaparib
- Group 2 will get a regimen of selumetinib alone
Study Details
Full Title
EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB:
PRO00114076
NCT:
NCT05554328
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment